Stock code: 688202 Stock abbreviation: Medicilon Announcement No.: 2025-015

Shanghai Medicililon Biopharmaceutical Co., Ltd

Announcement on the progress of the repurchase of the company's shares by means of centralized bidding transactions

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important Content Notes:

The repurchase plan was first disclosed on December 28, 2024, by Chen Jin, the actual controller of the company and the chairman at the time

Mr. Zhang, the actual controller, the then director and the general manager

MR. CHUN-LIN CHEN PROPOSED

The implementation period of the repurchase plan is 6 months after the approval of the company's general meeting of shareholders

The estimated repurchase amount is 50 million yuan ~ 100 million yuan

√ reduce the registered capital

Buyback Purpose √ for employee stock ownership plans or equity incentives

□ is used to convert the company's convertible bonds

□ to maintain the company's value and shareholders' rights

The cumulative number of shares repurchased is 00000 shares

Cumulative number of repurchased shares to total share capital 0%

The cumulative amount of repurchase is 00,000 yuan

The actual repurchase price range is 0 yuan/share~0 yuan/share

1. The basic situation of the repurchase of shares

Shanghai Medicilon Biopharmaceutical Co., Ltd. (hereinafter referred to as the "Company") in December 2024

On January 27, 2025, the 26th meeting of the third board of directors and the first interim meeting of 2025 will be held

The general meeting of shareholders deliberated and passed the "Proposal on the Plan for Repurchasing the Company's Shares by Centralized Bidding", and agreed that the Company would use its own funds and repurchase special loans to repurchase part of the Company's issued RMB ordinary shares (A shares) through the Shanghai Stock Exchange trading system through centralized bidding, and use the aforesaid repurchased shares for the Company's equity incentive or employee stock ownership plan or cancellation and reduce the Company's registered capital at an appropriate time in the future. Among them, the number of shares intended to be used for equity incentive or employee stock ownership plan shall not be less than 50% of the total amount of actual repurchase, and the number of shares intended for cancellation and reduction of registered capital shall not be higher than 50% of the total actual amount repurchased. The total amount of funds repurchased by the company this time shall not be less than RMB 50 million (inclusive) and not more than RMB 100 million (inclusive) for the repurchase of shares

The price shall not exceed RMB 54 per share (inclusive), and the period for repurchasing shares shall be within 6 months from the date of approval of the share repurchase plan by the general meeting of shareholders of the company.

For details, please refer to the company's announcement on December 28, 2024 and January 25, 2025 respectively in Shanghai Securities

Announcement of Shanghai Medicilon Biopharmaceutical Co., Ltd. on the Share Repurchase Plan by Centralized Bidding (Announcement No.: 2024-062) and Repurchase Report of Shanghai Medicilon Biopharmaceutical Co., Ltd. on Repurchase of Shares by Centralized Bidding (Announcement No.: 2025-011) disclosed on the website of the exchange (www.sse.com.cn).

2. Progress of share repurchases

According to the Rules for Share Repurchase of Listed Companies, the Self-Regulatory Guidelines for Listed Companies on the Shanghai Stock Exchange No. 7 - Repurchase of Shares, and other relevant regulations, the company shall announce the progress of the repurchase as of the end of the previous month within the first three trading days of each month. The progress of the company's share repurchase is hereby announced as follows:

As of March 31, 2025, the Company has not traded through the Shanghai Stock Exchange system through centralized bidding

way to repurchase the company's shares.

3. Other matters

The company will strictly follow the relevant provisions of the "Rules for Share Repurchase of Listed Companies", "Self-Regulatory Guidelines for Listed Companies on the Shanghai Stock Exchange No. 7 - Repurchase of Shares" and the company's share repurchase plan, make repurchase decisions and implement them according to market conditions during the repurchase period, and at the same time fulfill the information disclosure obligations in a timely manner according to the progress of the repurchase of shares, please pay attention to the investment risks.

The announcement is hereby made.

Board of Directors of Shanghai Medicilon Biopharmaceutical Co., Ltd

April 2, 2025